'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA
- 27 March 1987
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 257 (12) , 1615-1617
- https://doi.org/10.1001/jama.257.12.1615
Abstract
3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"), a synthetic analogue of 3,4-methylenedioxyamphetamine, has been the center of recent debate over its potential for abuse vs its use as a psychotherapeutic agent. Following its emergency classsification in Schedule 1 by the Drug Enforcement Administration in 1985, 3,4-methylenedioxyethamphetamine (MDEA, "Eve") has appeared as MDMA''s legal replacement. MDMA is thought to be safe by recreational users and by psychotherapists who support its used. The details of five deaths associated with the use of MDMA and MDEA are reported. In three patients, MDMA or MDEA may have contributed to death by the induction of arrhythmias in individuals with underlying natural disease. In another patient, use of MDMA preceded an episode of bizarre and risky behavior that resulted in accidental death. In another patient, MDMA was thought to be the immediate cause of death. Death as consequence of the use of these drugs appears to be rare, but it does occur; this outcome may be more common in individuals with underlying cardiac disease.This publication has 3 references indexed in Scilit:
- Methylenedioxyamphetamine. Clinical description of overdose, death, and review of pharmacologyArchives of internal medicine (1960), 1981
- 3,4-Methylenedioxyamphetamine OverdoseClinical Toxicology, 1979
- A Rapid, Comprehensive Screening Procedure for Basic Drugs in Blood or Tissues by Gas ChromatographyJournal of Analytical Toxicology, 1978